$1.52
0.65% yesterday
Nasdaq, Aug 11, 10:14 pm CET
ISIN
US5894921072
Symbol
MREO

Mereo BioPharma Group plc Sponsored ADR Stock price

$1.52
-0.09 5.59% 1M
-1.38 47.59% 6M
-1.98 56.57% YTD
-2.20 59.14% 1Y
+0.37 32.17% 3Y
-1.25 45.13% 5Y
-4.98 76.62% 10Y
-4.98 76.62% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.01 0.65%
ISIN
US5894921072
Symbol
MREO
Industry

Key metrics

Basic
Market capitalization
$243.3m
Enterprise Value
$180.8m
Net debt
positive
Cash
$62.5m
Shares outstanding
795.0m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 7.5
EV/Sales
- | 5.6
EV/FCF
negative
P/B
4.1
Financial Health
Equity Ratio
79.8%
Return on Equity
-70.9%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $33.6m
EBITDA
- | $-19.9m
EBIT
- | $-33.4m
Net Income
- | $-43.4m
Free Cash Flow
$-33.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | 57.1%
EBIT
- | 29.5%
Net Income
- | -0.3%
Free Cash Flow
-10.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -59.1%
EBIT
-
Net
- | -129.1%
Free Cash Flow
-
More
EPS
-
FCF per Share
$0.0
Short interest
8.7%
Employees
33
Rev per Employee
$0.0
Show more

Is Mereo BioPharma Group plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Mereo BioPharma Group plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Mereo BioPharma Group plc Sponsored ADR forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Mereo BioPharma Group plc Sponsored ADR forecast:

Buy
93%
Hold
7%

Financial data from Mereo BioPharma Group plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 26 26
12% 12%
-
- Research and Development Expense 21 21
23% 23%
-
-46 -46
7% 7%
-
- Depreciation and Amortization 1.09 1.09
3% 3%
-
EBIT (Operating Income) EBIT -47 -47
7% 7%
-
Net Profit -43 -43
0% 0%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mereo BioPharma Group plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mereo BioPharma Group plc Sponsored ADR Stock News

Positive
Seeking Alpha
about one month ago
Mereo BioPharma Group plc's phase 3 ORBIT study for setrusumab in osteogenesis imperfecta will continue to final analysis, expected by end of 2025. The recent 35% MREO stock drop was due to not meeting early efficacy stopping criteria of ORBIT, not due to safety or trial failure. The ongoing phase 2/3 ORBIT study is targeting OI patients ages 5 to 25, while the phase 3 COSMIC trial is going aft...
Negative
Investors Business Daily
about one month ago
Ultragenyx and Mereo stocks crashed Thursday after their treatment for brittle bone disease missed its mark in a second interim look.
Neutral
GlobeNewsWire
3 months ago
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the fi...
More Mereo BioPharma Group plc Sponsored ADR News

Company Profile

Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease. The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Denise Scots-Knight
Employees 33
Founded 2015
Website www.mereobiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today